EUCTR2009-014833-26-IT进行中（未招募）不适用
Phase IIB Randomized, Placebo Controlled Trial of Pioglitazone for Oral Premalignant Lesions. An Inter-Consortium Collaborative Study. - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Males or females with a suspected or histologically confirmed oral premalignant lesion of 8 mm or greater and width of 3 mm or greater in size. Age ≥18 years Life expectancy is > 6 months ECOG performance status is 0 or 1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-active cancer or carcinoma in situ of the head and neck. -contraindication to biopsy. -congestive heart failure (New York Heart Association (NYHA) Class II-IV), uncontrolled hypertension (systolic >150 or diastolic >100), or unstable angina. The participant has any history of congestive heart failure or history of myocardial infarction within the past 6 months. The participant exhibits clinical evidence of active liver disease or history of chronic liver disease The participant has > CTCAE Grade 1 edema The participant has known diabetes and is on insulin or oral agents. The participant is receiving medical therapy for dysregulated blood sugar. The participant has a random blood glucose level >200 mg/dl.
研究者
相似试验
进行中（未招募）
不适用
Phase 2A clinical trial conducted on children affected by Rett syndrome and who are casually administered with the experimental treatment, EPI-743, compared versus the se of placebo.EUCTR2012-005021-76-ITEDISON PHARMACEUTICALS INC.
进行中（未招募）
不适用
A Phase II, Randomised, Placebo-Controlled Trial of the Safety, Efficacy, Pharmacodynamics of PTX3003 in Patients with Charcot-Marie-Tooth Disease Type 1A - non applicableCharcot-Marie-Tooth disease (type 1A).MedDRA version: 12.1Level: LLTClassification code 10008414Term: Charcot-Marie-Tooth diseaseEUCTR2010-023097-40-FRPharnext80
进行中（未招募）
不适用
A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-936557 in Subjects with Active Ulcerative Colitis (UC)EUCTR2010-022506-41-ITBristol-Myers Squibb International Corporation386
进行中（未招募）
不适用
Induction and Maintenance Study of BMS-936557 Patients with Moderateto Severe Ulcerative ColitisColitis, UlcerativeMedDRA version: 16.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2010-022506-41-ATBristol-Myers Squibb International Corporation386
已完成
2 期
A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-936557 in Subjects with Active Ulcerative Colitis (UC)10017969Ulcerative ColitisNL-OMON35771Bristol-Myers Squibb12